The effect of autologous serum eyedrops in the treatment of severe dry eye disease: A prospective randomized case-control study

Kojima, Takashi; Ishida, Ryôhei; Doğru, Murat; Goto, Eiki; Matsumoto, Yukihiro; Kaido, Minako; Tsubota, Kazuo

doi:10.1016/j.ajo.2004.08.040

Cited by 212 publications

(221 citation statements)

References 20 publications

Supporting

Mentioning

211

Contrasting

Unclassified

Order By: Relevance

“…[105][106][107] Soro autólogo tem sido utilizado porque contém vitaminas, diversos fatores de crescimento e fibronectina, que são importantes para a integridade da córnea e conjuntiva. 108,109 Soro autólogo é indicado para o tratamento da xeroftalmia grave associada à DECH-c ocular para renovar os componentes do filme lacrimal e da superfície ocular.…”

Section: Terapia Adjuvante Para Dech-c Com Envolvimento Oralunclassified

Diretrizes para o diagnóstico, classificação, profilaxia e tratamento da doença enxerto contra hospedeiro crônica

Bouzas¹,

Silva²,

Tavares³

et al. 2010

Rev. Bras. Hematol. Hemoter.

View full text Add to dashboard Cite

Section: Terapia Adjuvante Para Dech-c Com Envolvimento Oralunclassified

Diretrizes para o diagnóstico, classificação, profilaxia e tratamento da doença enxerto contra hospedeiro crônica

Bouzas¹,

Silva²,

Tavares³

et al. 2010

Rev. Bras. Hematol. Hemoter.

View full text Add to dashboard Cite

“…Briefly, the visual analog symptom scales were prepared as 10-cm lines and the patients were requested to write down the worst symptom and to check a point on the line corresponding to the degree of their worst symptom. 18 Tear function parameters Tear evaporation rate. The tear film evaporation rate was measured as described previously 19,20 by using a tear evaporimeter (KAO Corporation, Tokyo, Japan) following the manufacturer's instructions.…”

Section: Methodsmentioning

confidence: 99%

Ocular surface and tear functions after topical cyclosporine treatment in dry eye patients with chronic graft-versus-host disease

Wang

Ogawa

Doğru

et al. 2007

Bone Marrow Transplant

108

View full text Add to dashboard Cite

We investigated the effect of 0.05% topical cyclosporine (Cys) on the ocular surface and tear functions in dry eye patients with chronic GVHD (cGVHD) in a prospective comparative study. Thirty eyes of 15 patients refractory to baseline treatment were recruited and the patients assigned for topical Cys treatment group (14 eyes of 7 patients) and control group (12 eyes of 6 patients) respectively. Two patients dropped out because of intolerable irritation while using topical Cys eye drops. Visual analog scale symptom scores, corneal sensitivity, Schirmer I test value, tear film break-up time (TBUT), tear evaporation rate and ocular surface vital staining scores were recorded at baseline and at the end of the following one month. Conjunctival impression and brush cytology were performed before and after the treatment. After topical Cys treatment, significant improvements were found in symptom scores, corneal sensitivity, tear evaporation rate, TBUT, vital staining scores, goblet cells density, conjunctival squamous metaplasia grade, inflammatory cell numbers and the MUC5AC expression. Our study suggests that 0.05% topical Cys may be an effective treatment for dry eye patients with cGVHD. The improvements in the ocular surface and tear functions resulted presumably from the decreased inflammation, increased goblet cell density and MUC5AC mRNA expression.

show abstract

“…Serum drops are totally nonallergenic and have biochemical properties similar to those of normal tears. Furthermore, serum drops support conjunctival epithelium with vitamins, fibronectin and growth factors which may stimulate its proliferation and repair [Geerling et al 2008;Kojima et al 2005]. From this point of view, platelet releasate seems to have a better growth factor concentration and seems to be a promising new treatment for dry eye [Liu et al 2006].…”

Section: Therapeutic Advances In Musculoskeletal Disease 2 (3)mentioning

confidence: 99%

Treating Sjögren’s syndrome: insights for the clinician

Vitali¹,

Palombi²,

Cataleta³

2010

Therapeutic Advances in Musculoskeletal

View full text Add to dashboard Cite

Sjögren's syndrome (SS) is a systemic autoimmune disease that affects the exocrine glands, mainly the salivary and lachrymal glands, with consequent persistent dryness of the mouth and eyes. In addition to the clinical manifestations related to the exocrine gland involvement, a consistent prevalence of patients may present systemic manifestations. Some of these can be ascribed to the periepithelial extension of lymphocytic infiltration whilst others are determined by an immunomediated process affecting small-or medium-size vessels. While the use of tear and saliva substitutes and local or systemic stimulation of residual secretions represent the mainstays of the therapy of sicca component, different immunomodulating or immunosuppressive agents are usually required to treat extraglandular features, similarly to what happens in other connective tissue diseases. In the last few years, the advancement in the understanding the pathogenetic mechanisms of this disorder and the availability of new biologic target therapies seem to offer completely new therapeutic options. The use of B cell depleting or modulating therapies has achieved promising results.

show abstract

The effect of autologous serum eyedrops in the treatment of severe dry eye disease: A prospective randomized case-control study

Cited by 212 publications

References 20 publications

Diretrizes para o diagnóstico, classificação, profilaxia e tratamento da doença enxerto contra hospedeiro crônica

Diretrizes para o diagnóstico, classificação, profilaxia e tratamento da doença enxerto contra hospedeiro crônica

Ocular surface and tear functions after topical cyclosporine treatment in dry eye patients with chronic graft-versus-host disease

Treating Sjögren’s syndrome: insights for the clinician

Contact Info

Product

Resources

About